Ambu makes single-use endoscopes and disposable airway devices, most notably the aScope bronchoscope and the aView monitor, which hospitals use to avoid the reprocessing and cross-infection risk of reusable scopes. The structural case rests on that consumables model: a 60.1% gross margin and recurring disposable volumes that tie hospital usage to Ambu's revenue rather than one-off capital sales. The near-term question is whether the business can convert that gross margin into operating profit, since the data we have shows 0.0% operating margin and flat 0.0% revenue growth, which is either a data gap or a sign the company is not yet earning a return on its growth spend. At 40.8x trailing and 25.8x forward earnings, the market is pricing in a recovery in profitability that has not yet appeared in reported numbers. With a 35/100 score and no index membership, this is a name to examine only if the operating margin and revenue lines are confirmed as reporting artifacts rather than real stagnation.
Plain-English pros, cons, and what to watch. Pro feature.
See what each model says, the assumptions behind it, the bad, normal and good cases, and why the fair value changed.
The full quality picture: a reason under every score, how the scores moved, and the conviction breakdown.
The full analyst picture: the price-target distribution against the current price, forward consensus estimates, and how ACCE's own models compare.
Trades are only made public after a delay. We show the delay so you know how old the news is.
Follow the informed money: 13F position changes, insider and Congress trades, and 13D activist filings.
| Date | Type | New | Previous | Price |
|---|---|---|---|---|
| 10 Oct 2026, 00:00 CEST | ACCE price target | kr 56.60 | first publication | kr 70.75 |
Answered from Ambu A/S fundamentals + recent valuations. Every number shows its source and date.
| Company | Price | Fair value | vs fair value | P/E | ROE | Quality | Score |
|---|---|---|---|---|---|---|---|
| AMBU-B.CO Ambu A/S | kr 79.30 | - | - | 41.3x | 0.0% | 50 | 37 |
| GN.CO GN Store Nord | kr 108.45 | kr 102 | 6% above | - | 2.1% | 37 | 46 |
| EKTA-B.ST Elekta AB (publ) | kr 56.30 | kr 51 | 10% above | - | -4.3% | 39 | 51 |
| HAE Haemonetics Corporation Common Stock | $116.16 | $68 | 72% above | 57.3x | 11.2% | 57 | 62 |
| NOLA-B.ST Nolato AB (publ) | kr 56.10 | kr 42 | 34% above | 20.8x | 13.1% | 64 | 51 |
| SECT-B.ST Sectra AB (publ) | kr 334.80 | kr 95 | 253% above | 104.4x | 28.3% | 85 | 68 |
| VITR.ST Vitrolife AB (publ) | kr 102.70 | kr 111 | 7% below | - | -46.5% | 56 | 39 |
Where AMBU-B.CO ranks against its sector peers on each metric.